INSL5
INSL5 is a member of the insulin superfamily, which encompasses a group of small, structurally similar peptide hormones including insulin, relaxin, and the insulin-like growth factors (IGFs). INSL5, or insulin-like peptide 5, was identified through genomic analyses as a novel member of this family. It is primarily expressed in the L-cells of the colon and has been implicated in various physiological processes, including the regulation of glucose metabolism, appetite control, and the gastrointestinal tract function.
Structure and Function[edit]
INSL5 consists of two peptide chains, A and B, that are connected by disulfide bonds, a characteristic feature of the insulin superfamily. The precise biological function of INSL5 remains an area of active research, but it is known to act through the G protein-coupled receptor RXFP4 (relaxin/insulin-like family peptide receptor 4), suggesting a role in signaling pathways that regulate energy homeostasis and metabolism.
Physiological Role[edit]
Emerging evidence suggests that INSL5 may play a role in the regulation of energy balance and body weight, potentially acting as an anorexigenic factor, which promotes the feeling of satiety and reduces food intake. Additionally, its expression in L-cells, which are known to secrete other hormones involved in appetite regulation such as glucagon-like peptide-1 (GLP-1), points to a synergistic role in the gut-brain axis, influencing metabolic processes and feeding behavior.
Clinical Significance[edit]
Given its involvement in metabolic regulation, INSL5 is being explored for its potential implications in metabolic disorders, including obesity and type 2 diabetes. Understanding the mechanisms by which INSL5 influences glucose metabolism and appetite could lead to new therapeutic targets for these conditions. Furthermore, the expression of INSL5 in the colon suggests it may also have roles in gastrointestinal health and diseases, although these functions are less well understood.
Research Directions[edit]
Future research on INSL5 is focused on elucidating its precise physiological roles and mechanisms of action. This includes studies aimed at understanding how INSL5 interacts with its receptor RXFP4 and other components of metabolic signaling pathways. Additionally, there is interest in exploring the therapeutic potential of INSL5 or its analogs in treating metabolic diseases and disorders associated with energy balance.
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
